STOCKWATCH
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultMay 13, 2026, 08:37 AM

Lite Strategy Q3 Net Loss $(23.7)M; Equity Up 235% on Digital Asset Strategy

AI Summary

Lite Strategy, Inc. reported a net loss of $(23.69) million for the three months ended March 31, 2026, a significant increase from $(2.57) million in the prior year. Despite the increased loss, the company's total assets grew to $57.79 million and stockholders' equity increased to $56.84 million, driven by a $100.0 million Private Investment in Public Equity (PIPE) offering in July 2025. The company has fully deployed its Litecoin Treasury Strategy, holding $40.32 million in digital assets, and initiated a $25.0 million share repurchase program. Regulatory clarity was provided with the SEC and CFTC classifying Litecoin as a "digital commodity."

Key Highlights

  • Net loss for the three months ended March 31, 2026, was $(23.69) million, up from $(2.57) million in 2025.
  • Net loss per share for the quarter was $(0.66), compared to $(0.39) in the prior year.
  • Total assets increased to $57.79 million as of March 31, 2026, from $18.29 million at June 30, 2025.
  • Total stockholders' equity rose to $56.84 million from $16.93 million over the same period.
  • Digital assets (current and long-term) totaled $40.32 million as of March 31, 2026.
  • Raised $92.19 million from a Private Investment in Public Equity (PIPE) offering in July 2025.
  • Authorized a $25.0 million share repurchase program, repurchasing $1.995 million of common stock.
  • SEC and CFTC classified Litecoin (LTC) as a "digital commodity" on March 17, 2026.
LITS
Biotechnology: Pharmaceutical Preparations
Lite Strategy, Inc.

Price Impact